Home › NDC Lookup › RxCUI directory › RxCUI 1543177

Tavaborole 43.5 MG/ML Topical Solution — RxCUI 1543177

RxNorm drug concept · Semantic clinical drug
RxCUI 1543177 Semantic clinical drug · SCD ● Current RxNorm concept 9 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1543177
Official nameTavaborole 43.5 MG/ML Topical Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astavaborole 5 % Topical Solution
FDA products mapped9
Package NDCs mapped11
Reported Medicaid activity (SDUD)11,126 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tavaborole Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tavaborole topical solution is used to treat a fungal infection of the toenails called onychomycosis. It works against the two fungi most commonly responsible — Trichophyton rubrum...
  • Yes, 48 weeks — about 11 months — is a long treatment course, and I understand that can feel like a lot. But here's the thing: toenails grow very slowly, and the fungus lives deep...
  • How long do I really need to use this for? That seems like a long time.
  • The most common side effects are local — some skin peeling, redness, or mild irritation right where you apply it, and occasionally an ingrown toenail. These are usually manageable....
📖 Read our full Tavaborole Topical guide →

🕸️ Concept Web — How Tavaborole 43.5 MG/ML Topical Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tavaborole 43.5 MG/ML Topical Solution RxCUI 1543177

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tavaborole 1543173
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Kerydin 1543178
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tavaborole Topical Solution 1543176
    • Tavaborole Topical Product 1543175
    • Tavaborole Topical Solution [Kerydin] 1543180
    • Kerydin Topical Product 1543181
    • Topical Solution 316986
    • Topical Product 1151122
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Tavaborole 43.5 MG/ML 1543174
    • Tavaborole 43.5 MG/ML Topical Solution [Kerydin] 1543182
    • Tavaborole 43.5 MG/ML [Kerydin] 1543179

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tavaborole 43.5 MG/ML SCDC · 1543174
  • Tavaborole Topical Solution SCDF · 1543176
  • Tavaborole Topical Product SCDG · 1543175

Brand-Name Concepts

  • Tavaborole 43.5 MG/ML Topical Solution [Kerydin] SBD · 1543182
  • Tavaborole 43.5 MG/ML [Kerydin] SBDC · 1543179
  • Tavaborole Topical Solution [Kerydin] SBDF · 1543180
  • Kerydin Topical Product SBDG · 1543181
  • Kerydin BN · 1543178

📦 FDA Products & Package NDCs

9 products · 11 package NDCs
11 package NDCs map to RxCUI 1543177 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
21922-0020-12 1 BOTTLE, WITH APPLICATOR in 1 CARTON (21922-020-12) / 10 m... Tavaborole Encube Ethicals, Inc. 2020-10-19
46708-0467-04 1 BOTTLE, DROPPER in 1 CARTON (46708-467-04) / 4 mL in 1 BO... Tavaborole Alembic Pharmaceuticals Limited 2025-02-18
46708-0467-10 1 BOTTLE, DROPPER in 1 CARTON (46708-467-10) / 10 mL in 1 B... Tavaborole Alembic Pharmaceuticals Limited 2025-02-18
62135-0663-59 10 mL in 1 BOTTLE, DROPPER (62135-663-59) Tavaborole Chartwell RX, LLC 2023-09-08
62332-0467-04 1 BOTTLE, DROPPER in 1 CARTON (62332-467-04) / 4 mL in 1 BO... Tavaborole Alembic Pharmaceuticals Inc. 2020-10-23
62332-0467-10 1 BOTTLE, DROPPER in 1 CARTON (62332-467-10) / 10 mL in 1 B... Tavaborole Alembic Pharmaceuticals Inc. 2020-10-23
69097-0686-37 1 BOTTLE, WITH APPLICATOR in 1 CARTON (69097-686-37) / 10 m... TAVABOROLE Cipla USA Inc. 2021-02-18
69238-1657-04 1 BOTTLE, WITH APPLICATOR in 1 CARTON (69238-1657-4) / 4 mL... Tavaborole Amneal Pharmaceuticals NY LLC 2020-11-28
69238-1657-06 1 BOTTLE, WITH APPLICATOR in 1 CARTON (69238-1657-6) / 10 m... Tavaborole Amneal Pharmaceuticals NY LLC 2020-11-28
70771-1826-00 1 BOTTLE, WITH APPLICATOR in 1 CARTON (70771-1826-0) / 10 m... Tavaborole Zydus Lifesciences Limited 2023-04-24
72578-0102-04 1 BOTTLE, WITH APPLICATOR in 1 CARTON (72578-102-04) / 10 m... Tavaborole Viona Pharmaceuticals Inc 2023-04-24
Observed labelers: Alembic Pharmaceuticals Inc. (2) · Alembic Pharmaceuticals Limited (2) · Amneal Pharmaceuticals NY LLC (2) · Chartwell RX, LLC (1) · Cipla USA Inc. (1) · Encube Ethicals, Inc. (1) · +3 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$3.5947
Range $3.5669–$3.5947 · middle 50% $3.5947–$3.5947 · 6 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.